Skip to main content

Pause Recommended

Two US federal agencies have called for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine so reports of a rare blood clot side effect may be investigated, the Wall Street Journal reports.

"We are recommending a pause in the use of this vaccine out of an abundance of caution," the Food and Drug Administration and the Centers for Disease Control and Prevention say in a joint statement. J&J's SARS-CoV-2 vaccine is a one-dose regimen that received Emergency Use Authorization from the FDA in March and, according to the FDA and CDC, about 6.8 million doses of the vaccine have been administered.

Six women developed cerebral venous sinus thrombosis with low blood platelet levels between six and 13 days after they received the J&J vaccine. The Journal reports that an outside panel is to review the data Wednesday for the CDC, while the FDA will perform its own investigation.

The Verge adds that the European Medicines Agency similarly announced it would be reviewing the J&J vaccine following reports of four cases of blood clots there. The EMA recently reviewed AstraZeneca's SARS-CoV-2 vaccine, which has also been tied to reports of rare blood clots, and the Journal notes that some countries have restricted the administration of the AstraZeneca vaccine to certain age groups.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.